Physician profile
Robert E Clark
NPI 1518944198
$1,573.70
in general payments reported to CMS, 2019-2025
18 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.89 · 2021: $175 · 2022: $538 · 2023: $229 · 2024: $306 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797 · Education: $49.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.00 |
| Education | $49.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $304.94 | 2021-2024 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $207.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.78 | 2022-2025 | |
| Akebia Therapeutics INC | $186.72 | 2021-2024 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $161.13 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $157.69 | 2024-2025 | |
| Lilly USA, LLC | $110.61 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $41.59 | 2020-2025 | Jynarque |
| Glaxosmithkline, LLC. | $36.04 | 2021-2023 | Benlysta |
| Travere Therapeutics, INC. | $26.26 | 2022-2024 | |
| Ardelyx, INC. | $26.11 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $22.91 | 2025 | Tarpeyo |
| Novo Nordisk INC | $20.17 | 2025 | Ozempic |
| Daiichi Sankyo INC. | $18.93 | 2021 | |
| Bard Peripheral Vascular, INC. | $17.32 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $15.23 | 2024 | Terlivaz |
| Siemens Medical Solutions USA, INC. | $14.50 | 2025 | Acuson Sequoia Diagnostic Ultrasound System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.45 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.